Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

2.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

3.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

4.

Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution.

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 13;11(7). pii: E979. doi: 10.3390/cancers11070979.

5.

Ischemia Is Related to Tumour Genetics in Uveal Melanoma.

Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1004. doi: 10.3390/cancers11071004.

6.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

7.

Radiation Treatment Affects Chromosome Testing in Uveal Melanoma.

Dogrusöz M, Kroes WG, van Duinen SG, Creutzberg CL, Versluis M, Bleeker JC, Marinkovic M, Luyten GP, Jager MJ.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5956-64. doi: 10.1167/iovs.15-17092.

PMID:
26393462
8.

Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.

Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, Jager MJ, Luyten GP, van der Velden PA.

PLoS One. 2015 Mar 12;10(3):e0116371. doi: 10.1371/journal.pone.0116371. eCollection 2015.

9.

Prognostic parameters in uveal melanoma and their association with BAP1 expression.

van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ.

Br J Ophthalmol. 2014 Dec;98(12):1738-43. doi: 10.1136/bjophthalmol-2014-305047. Epub 2014 Aug 21.

10.

Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma.

Bronkhorst IH, Maat W, Jordanova ES, Kroes WG, Schalij-Delfos NE, Luyten GP, Jager MJ.

Arch Pathol Lab Med. 2011 Aug;135(8):1042-7. doi: 10.5858/2010-0477-OAR1.

PMID:
21809997
11.

A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).

Blom E, Heyning FH, Kroes WG.

Cancer Genet Cytogenet. 2010 Oct 1;202(1):38-42. doi: 10.1016/j.cancergencyto.2010.06.004.

PMID:
20804919
12.

Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1.

Leeksma OC, Van Achterberg TA, Tsumura Y, Toshima J, Eldering E, Kroes WG, Mellink C, Spaargaren M, Mizuno K, Pannekoek H, de Vries CJ.

Eur J Biochem. 2002 May;269(10):2546-56.

Supplemental Content

Loading ...
Support Center